Monday, February 18, 2008 3:41:17 PM
Q on FDA enoxaparin generics issue.
Is this immune issue likely to be general question in the FoB space?
[OK, I known that technically heparins are not biologics, but that seams more like govenment nonsence to me than science]
If so, could MNTA get a nice adavantage in the FoB space by both getting a better understanding of the FDA requests, and also by pushing their views on achieving biosimilar status?
I'm clueless here
Is this immune issue likely to be general question in the FoB space?
[OK, I known that technically heparins are not biologics, but that seams more like govenment nonsence to me than science]
If so, could MNTA get a nice adavantage in the FoB space by both getting a better understanding of the FDA requests, and also by pushing their views on achieving biosimilar status?
I'm clueless here
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
